-->

Company Registry

Nacelle Therapeutics Inc
Profile last edited on: 12/27/2006

NO Business Identifier is currently available for this company.
Year Founded
2000
First SBIR Year
2002
Latest SBIR Award
2004
Program Status
Inactive

WikiProfile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1500 Hayes Drive
Manhattan, KS 66502
   (785) 532-3901
   jtomich@ksu.edu
   N/A
Multiple Locations:   
Congressional District:   01
County:   Riley

Public Profile

Nacelle Therapeutics Inc develops and commercializes treatments for cystic fibrosis based on research at the University of Kansas Medical Center. Nacelle Therapeutics research team developed a novel family of transmembrane, ion channel forming peptides that show great promise for cystic fibrosis therapy

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
---
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount Project Title
2004 1 NIH $232,945
Enhanced Drug Access to Eye Tissues
2002 1 NIH $100,000
Synthetic Peptide Modulators of Paracellular Conductance
2002 1 NIH $195,000
Channel Replacement Therapy for Cystic Fibrosis

Key People / Management

  Gary Rabold -- President

  John M Tomich --

SBIR firms in the news

There are no news available.